Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | CTSG | P08311 | 1/20 | 0.46 |
| ▸ | CMA1 | P23946 | 1/20 | 0.46 |
| ▸ | CTRC | Q99895 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9832282 | 0.88 | ADRB1 (0.47) | ADRB1MEN1KMT2AALOX5AKR1C3 | |
| SCHEMBL6802924 | 0.88 | MEN1 (0.57) | ADRB1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL10063748 | 0.81 | ADRB1 (0.70) | ADRB1MEN1KMT2AAKR1C3MAPT | |
| SCHEMBL3414344 | 0.81 | ADRB1 (0.70) | ADRB1MEN1KMT2AAKR1C3MAPT | |
| SCHEMBL7105773 | 0.81 | ADRB1 (0.70) | ADRB1MEN1KMT2AAKR1C3MAPT | |
| SCHEMBL26821274 | 0.79 | MGLL (0.50) | MEN1KMT2AMAPTLMNAKDM4E | |
| SCHEMBL578474 | 0.78 | AKR1C3 (0.47) | MEN1KMT2AAKR1C3MAPTLMNA | |
| SCHEMBL20907468 | 0.78 | LMNA (0.54) | MEN1KMT2AMAPTLMNAKDM4E | |
| SCHEMBL7284125 | 0.78 | MAPT (0.50) | MEN1KMT2AMAPTLMNAKDM4E | |
| SCHEMBL77364 | 0.78 | MAPT (0.57) | MEN1KMT2AF2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240537-B1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2020-09-09 | — | — | EP | disclosed |
| EP-3240537-B1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2020-09-09 | — | — | EP | disclosed |
| CN-107108610-B | Novel tetrahydropyridopyrimidine and tetrahydropyridopyridine compounds for the treatment and prophylaxis of hepatitis B virus infections | 豪夫迈·罗氏有限公司 | 2019-06-04 | — | — | CN | disclosed |
| US-10196391-B2 | Tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10196391-B2 | Tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2019-02-05 | — | — | US | disclosed |
| WO-2019022223-A1 | CYCLIC AMINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | 東レ株式会社 | 2019-01-31 | — | — | WO | disclosed |
| EP-3240537-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2017-11-08 | — | — | EP | disclosed |
| US-20170298067-A1 | NOVEL TETRAHYDROPYRIDOPYIMIDINES AND TETRAHYDROPRIDOPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170298067-A1 | NOVEL TETRAHYDROPYRIDOPYIMIDINES AND TETRAHYDROPRIDOPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170298067-A1 | NOVEL TETRAHYDROPYRIDOPYIMIDINES AND TETRAHYDROPRIDOPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2017-10-19 | — | — | US | disclosed |
| EP-1360184-A1 | PIPERIDINEE DERIVATIVES AS NEUROKININ 1 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-12 | — | — | EP | disclosed |
| WO-2002062784-A1 | PIPERIDINEE DERIVATIVES AS NEUROKININ 1 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-15 | — | — | WO | disclosed |
| US-5625046-A | Hydroxyl projecting groups for organic synthesis | KING'S COLLEGE LONDON (GB) | 1997-04-29 | — | — | US | disclosed |
| US-5608062-A | Process for preparing trifluoromethyl ketones | HOECHST SCHERING AGREVO GMBH (DE) | 1997-03-04 | — | — | US | disclosed |
| US-5436331-A | Etherification with N-aryl-4-alkoxy-1,2,5,6-tetrahydropyidine | KINGS COLLEGE LONDON (GB) | 1995-07-25 | — | — | US | disclosed |
| EP-0298982-B1 | PROTECTING GROUPS FOR ORGANIC SYNTHESIS | KING'S COLLEGE LONDON (GB) | 1991-08-28 | — | — | EP | disclosed |
| EP-0240398-B1 | DISSYMMETRICAL 1,4-DIHYDROPYRIDINE-3,5-DICARBOXYLIC-ACID DERIVATIVES, PREPARATION PROCESSES AND THERAPEUTICAL USE | FOURNIER INNOVATION ET SYNERGIE (FR) | 1991-05-15 | — | — | EP | disclosed |
| US-4900833-A | HYPOTENSIVE AGENTS | SOCIETE DE RECHERCHES INDUSTRIES (S.O.R.I.) (FR) | 1990-02-13 | — | — | US | disclosed |
| US-4806544-A | ENANTIOMORPHS, RACEMIC MIXTURES, HYPOTENSIVE AGENTS, CARDIOV LAR DISORDERS | FOURNIER INNOVATION ET SYNERGIE (FR) | 1989-02-21 | — | — | US | disclosed |
| EP-0240398-A1 | Dissymmetrical 1,4-dihydropyridine-3,5-dicarboxylic-acid derivatives, preparation processes and therapeutical use | FOURNIER INNOVATION ET SYNERGIE (FR) | 1987-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298067-A1 | NOVEL TETRAHYDROPYRIDOPYIMIDINES AND TETRAHYDROPRIDOPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | TPX2, QDPR, TPMT | ADRB1 1119/4885MEN1 2567/4885KMT2A 2296/4885 |
| US-10196391-B2 | Tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis B virus infection | TPMT, TYMP, DPYD | ADRB1 1412/4885MEN1 2480/4885KMT2A 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.